Dosage and administrationAfobazole ® should be taken following meals. The normal daily dose is 30 mg: 10 mg thrice daily (morning, afternoon and evening). The duration of a course of treatment is 2 - 4 weeks. If needed, the daily dose can be raised to 60 mg and the course length extended to 3 months.
Allergic reactions, occasional headaches.
Sedative effect and sleepiness are possible; they should be treated with caffeine.
Country of Manufacture: Russia
US Domestic shipping is available for this product! Choose Ships from: US size option to get it in 3-7 days to any US address. Dont forget to choose US Domestic Shipping when checking out.
Fabomotizole is an anxiolytic drug developed in the beginning of 2000s by the Russian Academy of Medical Sciences. It is currently available commercially under the trade name of Afobazole.
The goal of researchers at that time was to create a selective anxiolytic agent that would not have the adverse effects of benzodiazepines. In the open studies, the drug appeared to be as effective for the treatment of generalised anxiety disorder as diazepam, while causing significantly fewer side effects.
The producers of Afobazole claim that it stabilizes and upregulates GABA and benzodizepame receptors, exhibits neuroprotective properties, and diminishes anxiety and tensions in the body. The drug is designed above all for people with asthenic personal traits such as emotianal lability, e.g. tendency to react emotionally to stressful situations.
Fabomotizole is used in Russia to treat the following symptoms:
- Generalized anxiety disorder symptoms, e.g. bad feelings, tensions in the body, irritability, tearfulness, fearfulness, etc.
- Various somatic (psycophysiological) disorders, e.g. asthma, irritable bowel syndrome, systemic lupus erythematosus, ishemic heart diseases, etc.
- Sleep disorders caused by anxiety
- Premenstrual syndrome
- Alcohol and nicotine withdrawal.
Country of Manufacture: Russia
Availability: in stock
- Neznamov et al (2001) Clinical study of the selective anxiolytic agent afobazolhttps://www.ncbi.nlm.nih.gov/pubmed/11548440
- VS Kudrin (2006) A comparative study of the effect of afobazole on brain monoamine systems in BALB/C and C57BL/6 micehttps://www.ncbi.nlm.nih.gov/pubmed/17153957
- A Uyanaev, V Fisenko (2006) Studies of long-term noopept and afobazol treatment in rats with learned helplessness neurosishttps://link.springer.com/article/10.1007/s10517-006-0327-5
- Davydova et al (2010) Neurochemical study of effects of the new anxiolytic drugs afobazol and ladasten on the synthesis and metabolism of monoamines and their metabolites in the brain structures of Wistar rat on the model of monoamine synthesis blockade induced by aromatic amino acid decarboxylase inhibitor NSD-1015https://www.ncbi.nlm.nih.gov/pubmed/20408420
- Reutova et al (2010) Anxiolytic afobazole action self-evaluated by patients with anxiety-asthenic disordershttps://www.ncbi.nlm.nih.gov/pubmed/21086645
- Volkova et al (2010) Comparative study of the interoceptive effects of afobazole and diazepamhttps://www.ncbi.nlm.nih.gov/pubmed/21254504
- Kryzhanovskyi et al (2011) Study of anti-ischemic effect of afobazole in experimental myocardial infarctionhttps://www.ncbi.nlm.nih.gov/pubmed/21240343
- Cuevas et al (2011) Afobazole modulates microglial function via activation of both sigma-1 and sigma-2 receptorshttps://www.ncbi.nlm.nih.gov/pubmed/21715561
- Seredenin et al (2013) On the mechanism of anti-ischemic effects of afobazolehttps://www.ncbi.nlm.nih.gov/pubmed/24288760
- Behensky et al (2013) Afobazole activation of σ-1 receptors modulates neuronal responses to amyloid-β25-35https://www.ncbi.nlm.nih.gov/pubmed/24006338
- Kadnikov et al (2015) Cytoprotective Effect of Afobazole and Its Main Metabolite M-11https://www.ncbi.nlm.nih.gov/pubmed/26033588
- TS Syunyakov, GG Neznamov (2016) Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: Results of a multicenter randomized comparative study of diazepamhttps://www.ncbi.nlm.nih.gov/pubmed/27636931
- Kryzhanovkii et al (2018) On the Mechanism of the Cardioprotective Action of σ1 Receptor Agonist Anxiolytic Fabomotizole Hydrochloride (Afobazole)https://www.ncbi.nlm.nih.gov/pubmed/30225699
- Ostrovkaya et al (2018) Antidiabetic Activity of Afobazole in Wistar Ratshttps://www.ncbi.nlm.nih.gov/pubmed/30225697